Further PRs were noted in 2 of 3 efficacy-evaluable patients with HR-positive/HER2-negative breast cancer, with SD lasting ≥24 weeks in one other; PRs were noted in 1 of 5 patients with TNBC and one patient with CRPC; an additional SD lasting ≥24 weeks was observed in a patient with TNBC. Here, ERBB2 is linked to breast cancer.